Evidence map›Paper›PMID 29312339›Full record

ReviewFrontiers in immunology2017

Natural Killer T Cells: An Ecological Evolutionary Developmental Biology Perspective.

Amrendra Kumar, Naveenchandra Suryadevara, Timothy M Hill, Jelena S Bezbradica, Luc Van Kaer, Sebastian Joyce

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 74 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Novel lipid antigens for NKT cells in cancer.Frontiers in immunology · 2023
    Review
  14. Frontiers in immunology · 2023
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Amrendra KumarDepartment of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, TN, United States.
Naveenchandra SuryadevaraDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, United States.
Timothy M HillDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, United States.
Jelena S BezbradicaThe Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom.
Luc Van KaerDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, United States.
Sebastian JoyceDepartment of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, TN, United States.
Vanderbilt University Medical Center · USVA Tennessee Valley Healthcare System · USUnited States Military Academy · USUniversity of Oxford · GB

Funding

Signaling Functions of the Tumor Suppressor CYLDR01AI064639 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SUN, SHAO-CONG · 2006 to 2014
$3.6M
MOLECULAR BASIS OF CDLDL AND NATURAL T CELL FUNCTIONR01AI042284 · NIAID · VANDERBILT UNIVERSITY · PI JOYCE, SEBASTIAN · 1998 to 2013
$3.1M
Regulation of T-cell function and autoimmune inflammation by deubiquitinases.R37AI064639 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SUN, SHAO-CONG · 2015 to 2021
$2.8M
Molecular Basis of iNKT Cell Ontogeny and FunctionR01AI061721 · NIAID · VANDERBILT UNIVERSITY · PI JOYCE, SEBASTIAN · 2006 to 2010
$2.1M
BcI-2 family in T lymphocyte homeostasisR01AI074754 · NIAID · DUKE UNIVERSITY · PI HE, YOU-WEN · 2009 to 2013
$1.9M
Mechanisms and consequences of iNKT cell anergyR01AI070305 · NIAID · VANDERBILT UNIVERSITY · PI VAN KAER, LUC · 2007 to 2011
$1.9M
Interleukin 4 Regulation of LymphocytesR01AI068149 · NIAID · VANDERBILT UNIVERSITY · PI BOOTHBY, MARK R · 2006 to 2010
$1.8M
Modulation of chronic vascular inflammation by iNKT cellsR01HL089667 · NHLBI · VANDERBILT UNIVERSITY · PI VAN KAER, LUC · 2009 to 2012
$1.5M
Molecular Basis of CD1d1 and Natural T Cell FunctionR21AI042284 · NIAID · VANDERBILT UNIVERSITY · PI JOYCE, SEBASTIAN · 2002 to 2002
$302k
Vaccinating at Mucosal Surfaces with Nanoparticle Conjugated Antigen and AdjuvantI01BX001444 · VA · VETERANS HEALTH ADMINISTRATION · PI JOYCE, SEBASTIAN · 2014 to 2022
–
BLRD VA I01 BX001444NHLBI NIH HHS R01 HL089667NIAID NIH HHS R01 AI042284NIAID NIH HHS R01 AI061721NIAID NIH HHS R01 AI064639NIAID NIH HHS R01 AI068149NIAID NIH HHS R01 AI070305NIAID NIH HHS R01 AI074754NIAID NIH HHS R21 AI042284NIAID NIH HHS R37 AI064639
6 · The paper itself

Abstract

Type I natural killer T (NKT) cells are innate-like T lymphocytes that recognize glycolipid antigens presented by the MHC class I-like protein CD1d. Agonistic activation of NKT cells leads to rapid pro-inflammatory and immune modulatory cytokine and chemokine responses. This property of NKT cells, in conjunction with their interactions with antigen-presenting cells, controls downstream innate and adaptive immune responses against cancers and infectious diseases, as well as in several inflammatory disorders. NKT cell properties are acquired during development in the thymus and by interactions with the host microbial consortium in the gut, the nature of which can be influenced by NKT cells. This latter property, together with the role of the host microbiota in cancer therapy, necessitates a new perspective. Hence, this review provides an initial approach to understanding NKT cells from an ecological evolutionary developmental biology (eco-evo-devo) perspective.

Indexed as

cancer immunotherapyevolutioninfectious diseasesmicrobiotaNKT cells

Identifiers

PMID29312339
PMCPMC5743650
OpenAlexW2781019566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.